July 27, 2017

Align Technology Announces Record Second Quarter 2017 Results


SAN JOSE, CA -- (Marketwired) -- 07/27/17 --

  • Q2 revenues up 32.3% year-over-year, up 14.9% sequentially to a record $356.5 million
  • Q2 Invisalign case shipments for North America and International were up year-over-year 27.6% and 37.4%, respectively
  • Q2 Invisalign case shipments to teenage patients up 37.6% year-over-year, up 12.6% sequentially reaching a milestone of 1 million teen patients who have started Invisalign treatment
  • Q2 diluted EPS $0.85, up 37.1% year-over-year

Align Technology, Inc. (NASDAQ: ALGN) today reported financial results for the second quarter ended June 30, 2017. Invisalign case shipments in the second quarter of 2017 (Q2'17) were 231.9 thousand, a 31.0% increase year-over-year. For Q2'17, revenues were $356.5 million, a 32.3% increase year-over-year, and net profit was $69.2 million, or $0.85 per diluted share, up 37.1% per diluted share compared to the same period in the prior year.

Commenting on Align's Q2 2017 results, Align Technology President and CEO Joe Hogan said, "Our second quarter results were better than expected across key financial metrics including revenue, volume, margins, and EPS. Q2 revenues increased 32.3% year-over-year driven by strong Invisalign case shipments across all channels and especially in the teen segment. Solid execution of our strategy and key investments continue to deliver strong growth across the board, with record Invisalign volume in almost every geography. The second quarter also had an all-time high of nearly 5,000 newly trained Invisalign doctors in a quarter. Our iTero scanner business also performed well this quarter with revenues up 36.7% year-over-year."

GAAP Summary Financial Comparisons

Second Quarter Fiscal 2017

  Q2'17 Q1'17 Q2'16 Q/Q Change Y/Y Change
Invisalign Case Shipments* 231,890 208,060 176,995 +11.5% +31.0%
Net Revenues $356.5M $310.3M $269.4M +14.9% +32.3%
  Clear Aligner** $321.0M $282.4M $243.4M +13.7% +31.9%
  Scanner & Services $35.4M $27.9M $25.9M +26.9% +36.7%
Net Profit $69.2M $69.4M $50.1M (0.3)% +37.9%
Diluted EPS $0.85 $0.85 $0.62 $0.00 +$0.23
Note: Changes and percentages are based on actual values and may effect totals due to rounding
* Invisalign Shipment figures does not include SmileDirectClub aligners
** Clear aligner revenue includes revenues from Invisalign clear aligners and SmileDirectClub aligners

As of June 30, 2017, Align had $676.6 million in cash, cash equivalents and marketable securities compared to $644.2 million as of March 31, 2017. During Q2'17, we paid $50 million under an accelerated stock repurchase plan ("ASR") in which we received an initial delivery of approximately 0.3 million shares of common stock. The final number of shares repurchased will be determined at completion of the ASR based on Align's volume-weighted average stock price during the term of the ASR, less an agreed upon discount. There remains approximately $250 million available for repurchases under the existing stock repurchase authorization.

On July 24, 2017, Align increased the revolving line of credit with SmileDirectClub, LLC to $30.0 million and purchased an additional 2% equity interest in SmileDirectClub for $12.8 million. As a result of this purchase, the Company now holds a 19% equity interest, on a fully diluted basis. Additionally, on July 24, 2017, Align entered into an agreement to purchase a new facility in Costa Rica for $26.1 million.

Q2 2017 Business Highlights

The following list highlights Align's key announcements for the second quarter:

  • Opens New Invisalign Treatment Planning Facility in Chengdu, China: Align announced its first manufacturing operations in China and represents the Company's commitment to geographic expansion and investment in the Asia Pacific region. The Chengdu Treatment Planning and Training Centre of Excellence will provide treatment planning services for Invisalign providers in China.
  • Launched TimeLapse Technology for Scan Comparisons and 1 Minute Scan: Align announced a software upgrade for its iTero Element® intraoral scanners that includes the ability to compare patient scans over time with the new TimeLapse technology, providing general practitioner dentists and orthodontists with enhanced visualization, assessment and communication tools. In addition, with the 1.5 software upgrade, patient scans can be completed in as little as 1 minute.
  • Receives U.S. Patents for SmartTrack Material: Align announced that two U.S. Patents, Nos. 9,655,691 and 9,655,693, have been issued by the United States Patent and Trademark Office (USPTO) for SmartTrack aligner material, used exclusively for Invisalign aligner treatment. Launched commercially in 2013, Align's proprietary SmartTrack material is an innovative multi-layer polymer that delivers more gentle, constant force to improve control of tooth movements with Invisalign clear aligners.
  • Reaches 1 Million Invisalign Teen-aged Patients: Align announced that 1 million teenage patients have started treatment with Invisalign, the most advanced clear aligner system in the world. This is a significant accomplishment for the company and its more than 100,000 Invisalign-trained doctors, reflecting increasing preference for Invisalign clear aligners for teenage orthodontic treatment.
  • Global Funding Awarded Toward Advancing Orthodontic and Dental Research: Align announced twelve recipients of research grants under the company's Annual Research Award Program. Now in its eighth year of funding, nearly $300,000 is being awarded for 2017 to researchers at universities in North America, Europe and Asia Pacific.
  • Launched Invisalign Brand Marketing Campaign: Align announced that it has launched a comprehensive, multi-million dollar marketing campaign for its Invisalign brand designed to challenge metal braces as the status quo method for straightening teen teeth.

Q3 2017 Business Outlook

For the third quarter of 2017 (Q3'17), Align provides the following guidance:

  • Invisalign case shipments in the range of 231 thousand to 234 thousand, up approximately 30% to 32% over the same period a year ago.
  • Net revenues in the range of $355 million to $360 million, up approximately 27% to 29% over the same period a year ago.
  • Diluted EPS in the range of $0.78 to $0.81, which includes $0.01 of excess tax benefit.

Align Web Cast and Conference Call

Align will host a conference call today, July 27, 2017 at 4:30 p.m. ET, 1:30 p.m. PT, to review its second quarter 2017 results, discuss future operating trends and the business outlook. The conference call will also be web cast live via the Internet. To access the webcast, go to the "Events & Presentations" section under Company Information on Align's Investor Relations web site at http://investor.aligntech.com. To access the conference call, please dial 201-689-8261. An archived audio web cast will be available beginning approximately one hour after the call's conclusion and will remain available for approximately 12 months. Additionally, a telephonic replay of the call can be accessed by dialing 877-660-6853 with conference number 13665263 followed by #. For international callers, please dial 201-612-7415 and use the same conference number referenced above. The telephonic replay will be available through 5:30 p.m. ET on August 10, 2017.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners and services. Align's products help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign provider in your area, please visit www.invisalign.com. For additional information about iTero digital scanning system, please visit www.itero.com.

Forward-Looking Statement

This news release, including the tables below, contains forward-looking statements, including statements regarding certain business metrics for the third quarter of 2017, including, but not limited to, anticipated net revenues, gross margin, operating expenses, operating profit, diluted earnings per share, tax rate and case shipments. Forward-looking statements contained in this news release and the tables below relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement. Factors that might cause such a difference include, but are not limited to, difficulties predicting customer and consumer purchasing behavior, Align's ability to protect its intellectual property rights, continued compliance with regulatory requirements, competition from existing and new competitors, the willingness and ability of our customers to maintain and/or increase product utilization in sufficient numbers, the possibility that the development and release of new products does not proceed in accordance with the anticipated timeline, the possibility that the market for the sale of these new products may not develop as expected, or that the expected benefits of new or existing business relationships will not be achieved as anticipated, the risks relating to Align's ability to sustain or increase profitability or revenue growth in future periods while controlling expenses, growth related risks, including capacity constraints and pressure on our internal systems and personnel, the security of customer and/or patient data is compromised for any reason, continued customer demand for our existing and new products, changes in consumer spending habits as a result of, among other things, prevailing economic conditions, levels of employment, salaries and wages and consumer confidence, the timing of case submissions from our doctors within a quarter, acceptance of our products by consumers and dental professionals, foreign operational, political and other risks relating to Align's international manufacturing operations, Align's ability to develop and successfully introduce new products and product enhancements and the loss of key personnel. These and other risks are detailed from time to time in Align's periodic reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission (SEC) on February 28, 2017, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, which was filed with the SEC on May 4, 2017. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

                 
ALIGN TECHNOLOGY, INC.                
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS        
(in thousands, except per share data)                
                 
    Three Months Ended   Six Months Ended
      June 30, 2017     June 30, 2016     June 30, 2017     June 30, 2016
                         
Net revenues   $ 356,482   $ 269,362   $ 666,823   $ 508,082
                         
Cost of net revenues     85,565     64,146     160,281     122,239
                         
Gross profit     270,917     205,216     506,542     385,843
                         
Operating expenses:                        
  Selling, general and adminstrative     162,964     121,467     314,112     233,677
  Research and development     24,384     18,613     47,188     33,696
    Total operating expenses     187,348     140,080     361,300     267,373
                         
Income from operations     83,569     65,136     145,242     118,470
                         
Interest and other income (expense), net     3,212     125     4,857     (302)
                         
Net income before provision for income taxes and equity in losses of investee     86,781     65,261     150,099     118,168
                         
Provision for income taxes     15,387     15,113     8,164     27,474
Equity in losses of investee, net of tax     2,215     -     3,336     -
                         
Net income   $ 69,179   $ 50,148   $ 138,599   $ 90,694
                         
Net income per share:                        
    Basic   $ 0.86   $ 0.63   $ 1.73   $ 1.14
    Diluted   $ 0.85   $ 0.62   $ 1.70   $ 1.11
                         
Shares used in computing net income per share:                        
    Basic     80,188     79,951     80,047     79,891
    Diluted     81,631     81,281     81,668     81,440
         
ALIGN TECHNOLOGY, INC.        
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS    
(in thousands)        
         
    June 30,
2017
  December 31,
2016
ASSETS            
             
Current assets:            
  Cash and cash equivalents   $ 358,182   $ 389,275
  Marketable securities, short-term     243,786     250,981
  Accounts receivable, net     291,694     247,415
  Inventories     35,133     27,131
  Prepaid expenses and other current assets     74,427     38,176
    Total current assets     1,003,222     952,978
             
Marketable securities, long-term     74,619     59,783
Property, plant and equipment, net     255,539     175,167
Equity method investments     41,724     45,061
Goodwill and intangible assets, net     91,308     81,998
Deferred tax assets     61,783     67,844
Other assets     22,992     13,320
             
    Total assets   $ 1,551,187   $ 1,396,151
             
LIABILITIES AND STOCKHOLDERS' EQUITY            
             
Current liabilities:            
  Accounts payable   $ 45,953   $ 28,596
  Accrued liabilities     158,838     134,332
  Deferred revenues     220,005     191,407
    Total current liabilities     424,796     354,335
             
Income tax payable     44,581     45,133
Other long term liabilities     3,522     1,294
    Total liabilities     472,899     400,762
             
Total stockholders' equity     1,078,288     995,389
             
    Total liabilities and stockholders' equity   $ 1,551,187   $ 1,396,151
                           
ALIGN TECHNOLOGY, INC.                          
STOCK-BASED COMPENSATION                          
(in thousands)                          
                           
  Q1   Q2   Q3   Q4   Fiscal   Q1   Q2
    2016     2016     2016     2016     2016     2017     2017
Stock-based Compensation (SBC)                                        
    SBC included in Gross Profit $ 961   $ 932   $ 995   $ 1,078   $ 3,966   $ 925   $ 768
    SBC included in Operating Expenses   11,563     12,767     12,716     13,136     50,182     13,887     13,477
      Total SBC Expense $ 12,524   $ 13,699   $ 13,711   $ 14,214   $ 54,148   $ 14,812   $ 14,245
                             
ALIGN TECHNOLOGY, INC.                            
INVISALIGN BUSINESS METRICS*                            
                             
                             
    Q1   Q2   Q3   Q4   Fiscal   Q1   Q2
      2016     2016     2016     2016     2016     2017     2017
Invisalign Average Selling Price (ASP):                                          
  Worldwide ASP   $ 1,255   $ 1,285   $ 1,285   $ 1,230   $ 1,265   $ 1,270   $ 1,285
  International ASP   $ 1,315   $ 1,345   $ 1,365   $ 1,315   $ 1,335   $ 1,325   $ 1,335
                                           
Invisalign Cases Shipped by Geography:                                          
  North America     110,500     114,855     115,900     122,555     463,810     132,885     146,510
  International     53,195     62,140     61,855     67,500     244,690     75,175     85,380
    Total Cases Shipped     163,695     176,995     177,755     190,055     708,500     208,060     231,890
      YoY % growth     25.2%     22.4%     20.5%     18.5%     21.5%     27.1%     31.0%
      QoQ % growth     2.1%     8.1%     0.4%     6.9%           9.5%     11.5%
                                           
Number of Invisalign Doctors Cases Were Shipped To:                                          
  North America     22,355     22,575     22,570     23,265     34,065     23,910     24,695
  International     11,280     12,485     12,720     13,635     20,415     14,955     16,570
    Total Doctors Cases Shipped To     33,635     35,060     35,290     36,900     54,480     38,865     41,265
                                           
Invisalign Doctor Utilization Rates*:                                          
    North America     4.9     5.1     5.1     5.3     13.6     5.6     5.9
      North American Orthodontists     10.4     10.7     11.1     11.3     36.6     12.6     13.6
      North American GP Dentists     3.0     3.1     3.0     3.2     7.6     3.1     3.3
    International     4.7     5.0     4.9     5.0     12.0     5.0     5.2
    Total Utilization Rates     4.9     5.1     5.0     5.2     13.0     5.4     5.6
    * # of cases shipped/# of doctors to whom cases were shipped
                                           
Number of Invisalign Doctors Trained:                                          
    North America     875     1,125     1,300     1,420     4,720     980     1,620
    International     1,605     1,760     1,315     2,280     6,960     2,280     3,255
      Total Doctors Trained Worldwide     2,480     2,885     2,615     3,700     11,680     3,260     4,875
      Total to Date Worldwide     106,270     109,155     111,770     115,470     115,470     118,730     123,605
                                           
                                           
Note: Historical public data may differ due to rounding. Additionally, rounding may effect totals.
*Invisalign business metrics exclude SmileDirectClub aligners.
   
ALIGN TECHNOLOGY, INC.  
BUSINESS OUTLOOK SUMMARY  
(unaudited)  
   
The outlook figures provided below and elsewhere in this press release are approximate in nature since Align's business outlook is difficult to predict. Align's future performance involves numerous risks and uncertainties and the company's results could differ materially from the outlook provided. Some of the factors that could affect Align's future financial performance and business outlook are set forth under "Forward Looking Information" above in this press release.
     
Financial Outlook    
(in millions, except per share amounts and percentages)  
     
  Q3'17 Guidance  
     
  GAAP  
     
Net Revenues $355.0 - $360.0  
     
Gross Margin 74.7% - 75.7%  
     
Operating Expenses $184.5 - $187.5  
     
Operating Margin 22.7% - 23.6%  
     
Net Income per Diluted Share $0.78 - $0.81 (1)
     
     
Business Metrics: Q3'17  
     
Case Shipments 231.0K - 234.0K  
Capital Expenditure $70M - $75M  
Depreciation & Amortization $9.5M - $10.0M  
Diluted Shares Outstanding 81.8M* (2)
Stock Based Compensation Expense $14.9M  
Effective Tax Rate 21.0% (1)
     
(1) Includes the benefit from the adoption of the new accounting standard update for share-based compensation
(2) Excludes any stock repurchases during the quarter  

Investor Relations Contact
Yin Cantor
Align Technology, Inc.
(408) 470-1044
ycantor@aligntech.com

Press Contact
Shannon Mangum Henderson
Ethos Communication, Inc.
(678) 261-7803
align@ethoscommunication.com

Source: Align Technology

News Provided by Acquire Media


Close window | Back to top

Copyright 2017 Align Technology, Inc.